PHARMACEUTICAL IP

Evolve Insights

Welcome to Evolve Insights!

Evolve Insights is your go-to source for expert analysis and strategic perspectives on pharmaceutical IP.

  • Read our Articles for the latest pharma IP news and analysis. Many of our articles were originally published on IPKat.
  • Register for our upcoming live Webinars and watch our previous webinars on-demand.
  • Subscribe to our newsletter to stay up to date.

Do you have questions about how the latest developments in IP might impact you? Our team of experts would love to hear from you.

Latest articles

All articles

Strict US written description and enablement requirement applied to ADCs and platform inventions (Seagen v Daiichi Sankyo)

The recent decision of the US Court of Appeals for the Federal Circuit in Seagen v. Daiichi Sankyo overruled the jury decision in the District Court to find an ADC linker platform patent invalid for both lack of written description and enablement. 

ViCo oral proceedings: Whatever happened to the in-person “Gold-Standard”?

We are now many years on from the pandemic conditions that initially led to the introduction of oral proceedings by video conferencing for Board of Appeal cases. But what happened to the “Gold Standard” of in-person proceedings promised by the EBA in G 1/21? 

UPC Court of Appeal tackles broad functional antibody claims (UPC_CoA_529/2024)

The global litigation saga involving Amgen’s PCSK9 antibodies has long served as a high-stakes test case for jurisdictional approaches to broad, functionally defined antibody claims. Following the US Supreme Court’s landmark finding of lack of enablement in Amgen v Sanofi, and the UPC Munich Central Division’s initial revocation of the equivalent European patent, all eyes…

Webinars

All webinars
  • On-demand

Unlocking the potential of cell & gene therapies with effective IP strategy

Recorded on: July 11, 2025
Discover how to transform ground-breaking cell & gene therapy science into commercial success with robust IP strategies.

Stay connected

Get the latest insights, news, and expert analysis on pharmaceutical IP delivered straight to your inbox.
Subscribe for updates